Is DNLI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DNLI. It does not provide personalized investment advice.

DNLI (Denali Therapeutics Inc. Common Stock) Stock Analysis - Financials

Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of August 24, 2026, DNLI trades at $25.07 with a market cap of $3.98B and a P/E ratio of -8.83. DNLI moved -0.04% today. Year to date, DNLI is +50.94%; over the trailing twelve months it is +63.62%. Its 52-week range spans $10.57 to $27.30. Analyst consensus is strong buy with an average price target of $36.00. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are DNLI's key financials?

DNLI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DNLI recently traded at $25.07. Market cap is $3.98B. P/E ratio is -8.83. Revenue is $3.60M.

DNLI Key Metrics

Key financial metrics for DNLI
Metric	Value
Price	$25.07
Market Cap	$3.98B
P/E Ratio	-8.83
EPS	$-2.84
Dividend Yield	0.00%
52-Week High	$27.30
52-Week Low	$10.57
Volume	508.88K
Avg Volume	0
Revenue (TTM)	$3.60M
Net Income	$-511.45M
Gross Margin	0.00%

DNLI Analyst Consensus

14 analysts cover DNLI: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.00.

Common questions about DNLI

What are DNLI's key financials?: DNLI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DNLI recently traded at $25.07. Market cap is $3.98B. P/E ratio is -8.83. Revenue is $3.60M.
Is DNLI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DNLI. It does not provide personalized investment advice.